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Structural features of the agonist leukotriene C4 (LTC4) derived from conformational analysis has led
to the development of an intuitive receptor model and the design of potential LTC4 antagonists, These
compounds are modelled, in which either phenoxymethyleneoxadiazole, N-phenylbenzamide or
phenyloxymethylenetetrazole functionality is incorporated as a planar equivalent of LTC4, The
trifluoromethyl group is introduced at the lipophilic binding pocket of the agonist.
Enzymic oxidation of arachidonic acid via the for agonist binding conformation, Six torsion' 5
lipoxygenase pathway gives rise to a group of were considered most critical to the conformation
biologically important mediators, the peptide of the molecule" (Figure I), Four conformers
leukotrienes (pLTs) C, D and E (LTC4, LTD4 and extracted from the potential energy wells within 5
LTE4) which have been identified as important , kcal/mol of the lowest energy were selected as
components of slow reacting substances of shown in Figure 2,
anaphylaxis (SRS-A)I.2, 1?~se' leukotrienes =. Conformational analysis revealed the existence
reported as' potent mediators of allergic," of folded conformations The hydrophilic portion
inflammat0!Y and other pathological events'. of the peptide chain tends to curl upon the triene
Leukotriene C4 has been shown to cause potent rti f th 1 1 S' '1 1 tl e3 po Ion 0 e mo ecu e. ImI ar y, :1
bronchoconstrictiorr', increased microvascular. h dr h bi t '1 1 1 b k t d th tri" 4' '5 Y op 0 IC at a so cur s ac owar s e ene
permeability", and airway mucous secretiorr', at the methylene between the two cis double
Development of antagonists of leukotriene C4 is of b d Th the three important com onents of, h lozi Li 11 ' on s. us. p
Immense p arma~o ogica mtere~t to treat a ergic the agonists are: an acidic hydrophilic group at one
asthma and other mflammatory diseases. end, hydrophobic region at the other end and the
In the present paper, we report an application of third part represented by a central planar triene'".
the computer-assisted molecular modelling On the basis of these structural features and
(CAMM) to develop a novel series of compounds interatomic distances, the lowest energy conformer
possessing LTC4 antagonist properties. Since no was identified as an active conformation and used
structural information is available about the in the design of potential LTC4 antagonists,
receptor active site, an indirect approach was
adopted to understand the important interactions
necessary for binding. Based on the natural agonist
and on the structure-activity relationships (SAR) of
known LTC4 antagonists, we have studied the
conformational properties of the LTC4. Each of the
conformer was evaluated and compared in search
Methods
All molecules in this study were built using
QUANTA8 version 4.0 and charges were assigned
by Gasteiger method", Each compound was energy
minimized using steepest descent until energy
changes for the entire structures were smaller than









Figure 1 - Receptor binding model of LTC4 showing the
torsions rotated during grid search.
Figure 2 - Super imposition of low energy conformations of
LTC4•
0.01 kcallmol per 250 steps. This was followed by
application of the Adopted-Basis Newton-Raphson
(ABNR) minimization until energy tolerance of
0.001 kcallmol was satisfied. In general, this
required 500 ABNR minimization steps.
Minimization of agonist (LTC4) was performed by
using 500 steps of steepest descent 1000 steps of
ABNR minimization methods. The conformational
space" of the agonist and modelled structures was
explored with systematic (Grid scan) search
algorithm" within QUANTA. Number of
conformers generated for agonist were 729 (steps
of 30° increment) and for modelled structures were
256. The lowest energy conformer was chosen for
flexible fitting method. All calculations were
performed using CHARMm12 version 22 running
on Silicon Graphics IRIS 4D/20 workstation.
Molecular Modelling Study
Compound design. Since the structure of the
LTC. receptor has not been known, our design of
antagonists binding to this receptor was based on
molecular modelling of the natural agonist and on
the structural features of known receptor
antagonists. ONO-RS-347 and ONO-RS-411
(Figure 3) belonging to the series of 8-
(benzoylamino)-2-(tetrazol-5yl)-I, 4-benzodioxans
and 8-(benzoylamino)-2(tetrazol-5yl)-4-oxo-4H-l-
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benzopyrans were shown to be potent antagonists
of LTC4 receptor", The hydrophobic phenylbutoxy
chain, present in these compounds was
incorporated in compound 1, and the N-
phenylbenzamide functionality was introduced in
compound 2 to mimic the planar triene region. On
the basis of interatomic distance 5.80A and
molecular modelling of possible groups that fill the
triene portion, led to the selection of
phenyloxymethylene substited 1,2,3-oxadiazole. It
is well documented that the compounds containing
oxadiazole unit exhibit anti-inflammatory
activity". Hence, we incorporated the oxadiazole
group with an aim to obtain potential antagonists
of LTC4• The trifluoromethyl group was introduced
based on two criteria: firstly, the replacement of
hydrogen atoms by fluorine in biologically active
molecules found to have significance on activity"
and secondly, the ability of fluorinated group to
change the lipophilicity and electronic character.
Presence of a fluorine containing group in the
lipophilic side chain would increase antagonistic
activity by increasing lipopilicity, The
phenyloxymethylene tetrazole group of compound
3 occupies the planar triene region, with a distance
of 6.17 A. The rationale for the addition of an
acidic functional group, a carboxylic acid, is based
on the molecular features of the LTC4• Thus, three





Conformational search analyses of
Leukotriene C4(L TC4). The conformational space
ofLTC4 was explored using grid scan. At each grid
point dihedral angles were constrained to a specific
grid value, thus 729 conformers were generated.
Four conformers which were within 5 kcal/rnol of
the lowest energy conformation (Table J) were
extracted from the potential energy wells and
subjected to 500 iterations of Adopted-Basis
Newton-Raphson minimization. The low energy
conformers were superimposed by flexible fitting
method. The weighted root mean square deviation
(RMS) of all superimpositions was 0.41A.
Conformational search analyses of LTC4
antagonists. Low energy conformations «Table
II) of each of the antagonists were obtained by
using grid search. Number of conformers
generated were 256 per compound followed by a
500 step minimization using Adopted-Basis
Newton-Raphson method. The C-O torsion angle
of 1was rotated by 179° from -60° (the change in
bond angle was 0°) in order to get a distance
similar in range to that of LTC4, the distance of the
acid binding region now being 5.28A. The small
change resulted in 1.13 kcal/mol increase in
conformational energy when calculated in vacuo.
The energy difference however, does not preclude
this conformation from being an active
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Table 1 - Conformational data of LTC4
Conf. Energy <1>, <1>, <1>, <1>. <1>, <1>.
kcal/
mol
1. -74.90 29.52 60.20 60.35 29.66 59.89 59.97
2. -72.746 29.76 60.23 60.37 29.48 59.76 30.40
3. -71.718 29.42 60.21 60.13 29.77 30.15 60.03
4. -70.776 29.57 60.01 60.13 29.91 30.14 30.09
Table II - Conformational data for low energy structures of
LTC4 antagonists
Compd Energy 1\>, 1\>, <1>, <1>.
kcal/rnol
1. 40.14 89.984 89.923 60.084 60.034
2. 34.31 59.937 30.165 - 0.056 89.925
3. -22.09 60.143 60.102 0.138 60.047
ONO-RS-347 15.99 0.136 29.911 60.116 89.951
Figure 4 - Superimposition of 1 (red) on LTC4 (blue) by
torsional flexible fitting.
conformation. For all other compounds, the lowest
energy conformers had distances similar to that of
the agonist; therefore the torsion angles were left
unaltered. Each of these conformers were taken for
torsional flexible fit with the agonist (Figure 4). In
all cases RMS values were between 0.15 and 0.2
A.
Conclusions
A hypothetical model for leukotriene C4
receptor was deduced from the conformational and
structure analysis of an agonist and on the basis of
known receptor antagonists. The three important
components of the receptor model were identified:
a lipophilic binding region, an acid binding region
and a planar triene region. Based on the principle
of complementarity in shape and properties that is
essential for receptor recognition, we have
designed three compounds with such features as
potential receptor antagonists. Phenoxymeth-
ylenetetrazole and phenoxymethyleneoxadiazole
were incorporated as receptor binding equivalents
of the triene unit of LTC4 and trifluoromethyl
substituent as lipophilic side chain. The structures
of potential receptor antagonists having been
derived, the low energy conformers were
superimposed on LTC4 and examined for
similarity. The low RMS values of torsional
flexible fit with LTC4 indicate that the three
compounds modelled may exhibit potential LTC4
receptor antagonist activity.
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